Immunogenicity of Biologics, Biopharmaceuticals & ATMPs
Bratislava, Slovakia, April 28, 2026
TL;DR
The rise of biologics and ATMPs has transformed treatment of serious diseases, yet unwanted immunogenicity remains a key limitation. This course delivers practical, in-depth insight into immunogenicity risk assessment and minimization, regulatory and quality requirements, ADA assay development, and monitoring strategies to reduce immunogenicity risks in medicinal products.
About the Event
The rise of biologics and ATMPs have revolutionized the treatment of many serious diseases. However, the issues of unwanted immunogenicity sometimes remain the key limitation to fully utilize their potential.
Therefore, the development of biologics with decreased immunogenicity risks is of the high importance. This is, however, a very complex and multifactorial challenge, that needs to be addressed in pre-clinical and clinical development.
This unique course provides a practical & in-depth understanding of immunogenicity risk assessment and risk minimization. It also brings clarifications on the latest quality & regulatory requirements for immunogenicity. You will gain insights into analytical assay development as well as into characterization and monitoring of ADAs with appropriate analytical tools.
Join us & take away the strategies to minimize the risks of immunogenicity for your medicinal products.
Organization
Immunogenicity of Biologics, Biopharmaceuticals & ATMPs is organized by Fleming
Date and Location
The course will take place in Bratislava, Slovakia on April 28, 2026.
Attendance to the this course is Online.
For more information, you can click here to access to the event website.